mozavaptan has been researched along with Polycystic Kidney Diseases in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baeßler, B; Benzing, T; Borgal, L; Dafinger, C; Franke, M; Göbel, H; Höhne, M; Koerber, F; Maintz, D; Persigehl, T; Schermer, B; Vechtel, J | 1 |
Gattone, VH; Harris, PC; Torres, VE; Wang, X | 1 |
Doggrell, SA | 1 |
Gattone, V; Harris, PC; Torres, VE; Wang, X | 1 |
1 review(s) available for mozavaptan and Polycystic Kidney Diseases
Article | Year |
---|---|
Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Drug Evaluation, Preclinical; Humans; Polycystic Kidney Diseases | 2004 |
3 other study(ies) available for mozavaptan and Polycystic Kidney Diseases
Article | Year |
---|---|
Magnetic resonance T2 mapping and diffusion-weighted imaging for early detection of cystogenesis and response to therapy in a mouse model of polycystic kidney disease.
Topics: Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cysts; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Early Diagnosis; Female; Humans; Image Processing, Computer-Assisted; Kidney; Longitudinal Studies; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Mutation; NIMA-Related Kinases; Polycystic Kidney Diseases; Proof of Concept Study; Time Factors; Treatment Outcome; Young Adult | 2017 |
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Aquaporin 6; Aquaporins; Benzazepines; Cyclic AMP; Disease Models, Animal; Disease Progression; Humans; Kidney; Mice; Polycystic Kidney Diseases; Proteins; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; TRPP Cation Channels | 2003 |
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
Topics: Adenine; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; Guanosine Triphosphate; Introns; Kidney; Male; Phosphorylation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Recessive; Proto-Oncogene Proteins B-raf; ras Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Thymine; Tolvaptan | 2005 |